QureBio Ltd. to Present its Q-1802 Clinical Phase Ⅰ Data at 2023 ASCO-GI Meetings
/PRNewswire/ -- QureBio Ltd., a clinical-stage biopharmaceutical company focusing on development of bispecific antibodies and other engineered...
Source: prnewswire.com